Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Specimen Handling 146pembrolizumab 120Magnetic Resonance Spectroscopy 117Cyclophosphamide 114Biopsy 97fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46venetoclax 41Radiotherapy 41Paclitaxel 40Cetuximab 40fludarabine phosphate 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 33Oxaliplatin 27Leucovorin 27Dexamethasone 27durvalumab 26X-Rays 25Irinotecan 25Radiation 24Cytarabine 24Azacitidine 24Injections 22Temozolomide 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Pharmacogenomic Testing × 90 days × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
48 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01165333 2026-03-16

CILENT

Centre Oscar Lambret

Phase 1 Completed
32 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡